EUVIMEDEUVIMED entdecken
Übersichtsarbeit

Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors

Weixi Yuan, Qiang Kang, Yin Zhao, Zhe Wang, Yujia He, Chengxiao Fu, Hongxiang Xiao, Xiaoyong Lei, Zhizhong Xie, Xiaoyan Yang, Bo Yang, Guotao Tang und 1 weitere

Cancer Chemotherapy and Pharmacology · 20.08.2026 · 96 (1)

DOI: 10.1007/s00280-026-04918-5 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancer Chemotherapy and Pharmacology, online erschienen am 20.08.2026. Verfasst von Weixi Yuan und 12 weiteren Autor:innen. Beteiligte Einrichtung: The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, He…. Hauptthemen laut MEDLINE: Neoplasms, Enzyme Inhibitors, Lactate Dehydrogenase 5, Antineoplastic Agents. Die Arbeit nennt 116 Literaturangaben. Gefördert von: Hunan Provincial Key Laboratory of Tumor Microenvironment responsive Drug Research, National Natural Science Foundation of China, Natural Science Foundation of Hunan Province.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

As a key enzyme in pyruvate metabolism, lactate dehydrogenase A (LDHA) has been extensively studied for its role in cellular energy regulation and disease pathology. Given its central role in the Warburg effect (cancer cells have a higher intensity of glycolysis even under oxygen-rich conditions) cytoplasmic LDHA emerges as a strategic therapeutic target for tumor suppression through glycolytic pathway inhibition. Despite extensive research, the development of effective LDHA inhibitors has seen limited success, highlighting the urgent need to reassess its molecular properties and refine drug design strategies. In this review, we systematically analyze LDHA's structural biology, critically evaluate the strengths and shortcomings of current inhibitors, and propose novel conceptual frameworks for inhibitor development based on recent insights into LDHA-mediated glycolysis reprogramming. By integrating recent insights into LDHA-mediated glycolysis reprogramming, this review lays the groundwork for rational inhibitor design and its clinical application, either as monotherapy or in combination treatments for cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

NeoplasmsEnzyme InhibitorsLactate Dehydrogenase 5Antineoplastic AgentsL-Lactate DehydrogenaseAntineoplastic Combined Chemotherapy ProtocolsHumansAnimalsGlycolysisDrug DesignMetabolic ReprogrammingWarburg Effect, Oncologic

Stichwörter der Autor:innen

Cancer therapeuticsChemoresistanceDrug combination strategyLDHA inhibitorsLactate dehydrogenase AMetabolic reprogrammingTumor metabolismWarburg effect

Substanzen

Enzyme InhibitorsLactate Dehydrogenase 5Antineoplastic AgentsL-Lactate DehydrogenaseLDHA protein, human

Autor:innen und Institutionen

  • The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • Pharmacy Department, The First People's Hospital of Xiangtan City, Xiangtan Hospital Affiliated to University of South China, Xiangtan, 411101, Hunan, PR China.
  • The Second Affiliated Hospital, Department of Pharmacy, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China.
  • Hunan Haopifu Pharmaceutical Co., Ltd, Hunan, China.
  • Department of Pharmacy, Xiangnan University, Chenzhou, 423000, China.
  • The First Affiliated Hospital, Department of Pharmacy, Institute of Pharmacy and Pharmacology, Hengyang Medical School, University of South China, Hengyang, 421001, Hunan, China. ybnhfy@126.com.

Förderung

  • Hunan Provincial Key Laboratory of Tumor Microenvironment responsive Drug Research
  • National Natural Science Foundation of China
  • Natural Science Foundation of Hunan Province

Zitieren

APA

Yuan, W., Kang, Q., Zhao, Y., Wang, Z., He, Y., Fu, C., Xiao, H., Lei, X., Xie, Z., Yang, X., Yang, B., Tang, G., & Deng, X. (2026). Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors. Cancer Chemotherapy and Pharmacology, 96(1). https://doi.org/10.1007/s00280-026-04918-5

Vancouver

Yuan W, Kang Q, Zhao Y, Wang Z, He Y, Fu C, et al. Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors. Cancer Chemotherapy and Pharmacology. 2026;96(1). doi:10.1007/s00280-026-04918-5

BibTeX
@article{Yuan2026,
  author = {Yuan, Weixi and Kang, Qiang and Zhao, Yin and Wang, Zhe and He, Yujia and Fu, Chengxiao and Xiao, Hongxiang and Lei, Xiaoyong and Xie, Zhizhong and Yang, Xiaoyan and Yang, Bo and Tang, Guotao and Deng, Xiangping},
  title = {Intensification versus combination: revisiting the past and envisioning the future of LDHA inhibitors},
  journal = {Cancer Chemotherapy and Pharmacology},
  year = {2026},
  volume = {96},
  number = {1},
  doi = {10.1007/s00280-026-04918-5}
}
Kostenlos starten →